Biosimilars Policy Roundup for September 2024—Podcast Edition
Season 6, Episode 37, Oct 06, 2024, 11:00 AM
Share
Subscribe
On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Show notes
1. FDA Approves Pavblu for Retinal Conditions
2. AAM Report: Generics and Biosimilars Savings Reach $445 Billion in 2023, Part 1
3. Expanding Biosimilar Adoption: Insights and Strategies With Dr Sophia Humphreys
4. The Future of Biosimilar Gene Therapies: Key Issues and Potential
5. IRA Reimbursement Impact on Biosimilars Minimal Despite Rising Market Share
6. The Role of Coverage Strategies in Biosimilar Market Impact and Cost Savings
7. France Study Finds High Patient Satisfaction With Adalimumab Biosimilar Treatment for IBD
2. AAM Report: Generics and Biosimilars Savings Reach $445 Billion in 2023, Part 1
3. Expanding Biosimilar Adoption: Insights and Strategies With Dr Sophia Humphreys
4. The Future of Biosimilar Gene Therapies: Key Issues and Potential
5. IRA Reimbursement Impact on Biosimilars Minimal Despite Rising Market Share
6. The Role of Coverage Strategies in Biosimilar Market Impact and Cost Savings
7. France Study Finds High Patient Satisfaction With Adalimumab Biosimilar Treatment for IBD